ASCO 2023: Day 1- Cervical Cancer, HIPEC, Antibody Drug Conjugates in Gyn Cancers

Note: Due to the number of Tweets embedded in this post the page may take some time to load.

This year I attended #ASCO23 virtually. Some of the sessions were available live but some were on-demand usually a day later. Many of the Tweets I will share in the next few posts were from those I follow who attended those sessions in person. 

Friday, June 2,2023

Clinical Science Symposium  

Cervical Cancer 

An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC):  A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).       Abtract LBA 5511

Marie Plante: Int’l P3 trial radical hysterectomy & pelvic node dissection (RH) vs simple hysterectomy & pelvic node dissection (SH) in pts w/low-risk early-stage cervical ca (LRESC): Gyn Cancer Intergroup study led by Canadian Cancer Trials Grp (CCTG CX.5-SHAPE) #ASCO23 #gyncsm pic.twitter.com/LKNcH98csJ

— Annie Ellis (@Stigetta) June 2, 2023

SHAPE trial @ #ASCO23: Simple hysterectomy has fewer urological surgical complications & better #QOL measures than radical hysterectomy w/ similar outcomes in pts w/ early-stage, low-risk #CervicalCancer: https://t.co/ZeilCAw71H @RauhHainMD @MDAndersonNews #ASCODailyNews #gyncsm pic.twitter.com/q64QRig1oE

— ASCO (@ASCO) June 2, 2023

 Read more about the above study at https://www.cancer.net/blog/2023-06/asco-annual-meeting-2023-less-extensive-hysterectomy-effective-early-cervical-cancer-and-adding?cmpid=ks_cancernet_net_awareness_sno_facebook_all__glob_060223____aware_photo-text_ 

These data from the SHAPE trial are incredible: the type of hysterectomy done for early cervical cancer can profoundly impact sexuality. #ASCO23 #gyncsm pic.twitter.com/GZE7OyXXOQ

— Don S. Dizon MD (he/him) 🇬🇺 (@drdonsdizon) June 3, 2023

 

 

 HIPEC in Ovarian Cancer

Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up. (Sonke  abstract 5509) 

Median follow up of 10.1 years. "One hundred and eight patients (87.8%) in the surgery group have died as compared to 100 patients (82.0%) in the surgery-plus-HIPEC group.Median recurrence-free survival was 10.7 months in the surgery group compared to 14.3 months in the surgery-plus-HIPEC group (HR, 0.63; 95% confidence interval [CI], 0.48-0.83; stratified P<0.001). This study provides the first long-term survival analysis of HIPEC in ovarian cancer and confirms the benefit of HIPEC in patients with primary stage III epithelial ovarian cancer undergoing interval cytoreductive surgery. "                                   Overall survival 44.9 with HIPEC versus 33.3 no HIPEC. 

HIPEC (OVhIPEC1) did not show benefit in BRCAm patients. #ASCO2023 #gyncsm pic.twitter.com/Usz5swhbnu

— BJ Rimel (@BJRimelMD) June 2, 2023

Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial. (abstract 5510)

"The CHIPOR multicentric randomized phase III trial (NCT01376752), conducted in 31 institutions, enrolled patients with a first platinum-sensitive relapse (platinum-free interval of ≥6 months) of EOC. Patients were treated with 6 cycles of platinum and taxane based CT ± bevacizumab, and those amenable to a complete cytoreductive surgery at the end of CT were enrolled and randomly assigned to receive HIPEC (cisplatin 75 mg/m² at 41°C for 60 min) or not. HIPEC significantly improves OS and peritoneal PFS of women with first platinum-sensitive relapse of EOC treated with second-line platinum-based CT followed by secondary complete cytoreductive surgery."

 

Another positive #HIPEC RCT in #ovarian cancer - Plat sens recurrence - #CHIPOR: OS benefit 8.6 mo, PFS benefit 1.3 mo. NACT SOC platinum (eg Carbo/doxil) +/- Bev -> HIPEC cisplatin 75mg/m2 x 60; 87% CC0. Congrats to #JMClasse #OGlehen #ASCO23 pic.twitter.com/XhExD3Ddz0

— Thanh Dellinger (@TDellingerMD) June 3, 2023

 

Education Session 

 Antibody Drug Conjugates: New Opportunities in Gynecologic Cancer

#gyncsm
Ovarian Cancer approved Mirvetuximab Soravtansine-gynx FR alpha
Additional ADCs being tested (STRO-002, UpRI etc) 2/3#ASCO23 pic.twitter.com/VmGf7vHO6K

— Dee Sparacio (@womenofteal) June 2, 2023

 

#ASCO23 #gyncsm Management of Unique Ocular Toxicities
Stella K. Kim, MD
Ocular side effects from ADCs and many other oncology treatments 1/4 pic.twitter.com/K9oWRcvOhg

— Dee Sparacio (@womenofteal) June 2, 2023

 

What makes treatment worth it@sachiasp #ASCO23 #gyncsm
* how we look at our mortality
*what do we hear you say
"We want some control over our own lives. "
"I may say I am not willing to let cancer take more..."
" look at us as a whole person
2/2 pic.twitter.com/bx3hoWpR50

— Dee Sparacio (@womenofteal) June 2, 2023

Dee

Every Day is a Blessing!

SGO 2022 Annual Meeting - Ovarian Cancer Research

Below find some interesting ovarian cancer research studies I heard at the SGO meeting.

Scientific Plenary II: Building Bridges - Pioneering Protocols and Scientific Progress

Long Term Survival of GOG 252 'Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/GOG Study' J. Walker

#SGOmtg. Dr Walker GOG 252 - no gross residual disease population - Can you completely resect? Can you get CA125 to less than 10 in 3 cycles. #gyncsm pic.twitter.com/qMksxlPgFx

— Dee Sparacio (@womenofteal) March 18, 2022

 

 What's Next After Bevaciumab Resistance? Targeting Metabolic Vulnerabilities in Ovarian Cancer –  D. Glassman GLSi is a novel therapeutic strategy to treat AVA-resistant ovarian cancer

#SGOmtG Dr Glassman : Bevaczumab resistance in OC
GLS expression GLS inhibitor and hypoxia , #gycsm pic.twitter.com/A7kjIBHIqB

— Dee Sparacio (@womenofteal) March 18, 2022

 

Final Overall Survival Results from SOLO3: Phase III Trial Assessing Olaparib Monotherapy Versus Non-Platinum Chemotherapy in Heavily Pretreated Patients with Germline BRCA1 and/or BRCA2-Mutated Platinum-Sensitive Relapsed Ovarian Cancer –  R. Penson

Investigation of PARP Inhibitor Resistance Through the Analysis of Serially Collected Circulating Tumor DNA (ctDNA) in Ovarian Cancer Patients – Speaker: Y. Kim 

#SGOMtg Dr Kim PARP progression and gene mutations #gyncsm pic.twitter.com/8BHkdtz1LK

— Dee Sparacio (@womenofteal) March 18, 2022

 

Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, in the US and Europe: A Real-World Chart Review Analysis (2017-2020) – Speaker: K. Moore

Dr Moore global study of use of maintenance therapy #SGOMtg #gyncsm pic.twitter.com/GQXBwelTEz

— Dee Sparacio (@womenofteal) March 18, 2022

 

Knowledge Measure for Ovarian Cancer Research (KnoMOR): Development and Psychometric Testing Results of a Patient-Centered Knowledge Measure – Speaker: L. Meyer

Yes!! Dr. Larissa Meyer: Knowledge is a prerequisite to informed choice. Development of KnoMOR (Knowledge Measurement for Ovarian Cancer Research) Shared decision making tool. #SGOmtg #GYNcsm pic.twitter.com/miuAi5ZGuD

— Annie Ellis (@Stigetta) March 18, 2022

Scientific Plenary II: Building Bridges - Pioneering Protocols and Scientific Progress

OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis – Speaker: M. Hardesty

 

Hardest OVARIO trial #SGOmtg heavily pretreated population.
53% had PFS at 28 months. S not available at this time. #gyncsm pic.twitter.com/wr9Ze4NMOP

— Dee Sparacio (@womenofteal) March 19, 2022

 

Prospective, Randomized Trial of Streamlined Genetic Education and Testing for Patients with High Grade Epithelial Ovarian, Fallopian and Peritoneal Cancer – Speaker: R. Previs

Dr. Rebecca Previs presents results of video assisted streamlined genetic education and testing for ovarian cancer #SGOmtg #GYNcsm #PECPatAdv pic.twitter.com/EkzCqvk3qo

— Annie Ellis (@Stigetta) March 19, 2022

 Effectiveness of Platinum-Based Chemotherapy after Progression on Poly ADP Ribose Polymerase (PARP) Inhibitor in Epithelial Ovarian Cancer – Speaker: K. Dugan

#SGOmtg Dr Dugan For patients who progress after PARP retreatment with platinum drugs is reasonable #gyncsm pic.twitter.com/AYBB2bjES7

— Dee Sparacio (@womenofteal) March 19, 2022

Scientific Plenary III: Novel Therapeutics: The Expanding Toolbox

A Novel Combo of Niraparib and Anlotinib in Platinum-Resistant Ovarian Cancer, the Final Efficacy and Safety Report of ANNIE Study, a Phase II, Multi-Center Trial – Speaker: J. Liu , This is a Niraparib and Anlotinib ( kinase inhibitor) combo used in Platinum-Resistant OC (ANNIE Study) Promising combo With tolerable toxicity . PPMD1 mutation may be what leads to resistance in niraparib.

 Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer – D. Richardson

#SGOmtg Ph1 Expansion Study of Upifitamab Rilsodotin (UpRi NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian
Cancer - Dr Richardson , 97 patients in 2 groups , no severe toxicity, prior lines
ORR 44% in NaPi 2b expression patients #gyncsm pic.twitter.com/c8a3Idtj0A

— Dee Sparacio (@womenofteal) March 19, 2022

Clinical Outcomes of Ovarian Cancer Patients Treated with the Novel Engineered Cytokine Nemvaleukin Alfa in Combination with the PD-1 Inhibitor Pembrolizumab: Recent Data from ARTISTRY-1 – Speaker: I. Winer

#SGOmtg Ovarian Cancer Treated with the Novel Engineered
Cytokine Nemvaleukin Alfa in Combination with the PD-1 Inhibitor Pembrolizumab ARTISTRY-1 – Dr I. Winer
16 patients treated, 5 had response. Well tolerated. Evidence of tumor response , FDA fast track Designation #gyncsm pic.twitter.com/9tyvTZFOvK

— Dee Sparacio (@womenofteal) March 19, 2022

 

Late Breaking Abstracts:

#SGOmtg Dr Matulonis Soraya study : High folate expressing ovarian cancer treated with mirvetuximab MIRV antibody drug conjugate ORR 34%, mDOR 6.9 months 5 complete responses mPFS 5.4 mo
AE ocular events( blurred vision) were reversible , nausea #gyncsm pic.twitter.com/oNV8XjpoEG

— Dee Sparacio (@womenofteal) March 19, 2022

#SGOmtg PRIME study - niraparib as maintenance in newly dx adv OC individual dosing
PFS 24.8 months with Niraparib vs 8.3 months in placebo
Immature OS . #gyncsm pic.twitter.com/kbAz1QBJzk

— Dee Sparacio (@womenofteal) March 20, 2022

#SGOmtg Dr Gershenson presenting on LGSOC using NGS
Characteristics : Young age, relative chem resistance, responds to endocrine therapy #gyncsm pic.twitter.com/QzYZfJ7SGw

— Dee Sparacio (@womenofteal) March 20, 2022

Dr David Gershenson presenting study showing better survival in women with low grade serous ovarian cancer whose tumors have MAPK mutations ⁦@RareOvarCancers⁩ #sgomtg pic.twitter.com/7c2ydfwwzN

— Karen Lu (@karenluMD) March 20, 2022

 

Scientific Plenary V: Bullseye! Precision Medicine and Hitting the Right Targets

RNAseq Correlative Biomarkers IFIT1B and VSTM5 Predict Progression Free Survival and Clinical Benefit in a Multi-Site Phase I/II Trial of Olaparib and Tremelimumab for gBRCAm Recurrent Ovarian Cancer –  S. Adams

#SGOMtg Dr Adams Olaparib and Tremelimumab ( CTLA4
In women with OC with BRCA mutations
Combo may be a benefit for a subset of women with OC #gyncsm pic.twitter.com/7rwhexJQ02

— Dee Sparacio (@womenofteal) March 20, 2022

#SGOMtg Dr Adams Olaparib and Tremelimumab ( CTLA4
In women with OC with BRCA mutations
Combo may be a benefit for a subset of women with OC #gyncsm pic.twitter.com/7rwhexJQ02

— Dee Sparacio (@womenofteal) March 20, 2022

Turning Cold into Hot: Combination of Pembrolizumab with Bevacizumab and Oral Metronomic Cyclophosphamide Increases Immune Cell Migration into the Tumor Microenvironment in Responding Patients with Recurrent Ovarian Cancer – N. Gaulin

The Role of Mesenchymal Stem Cells in the Ovarian Cancer Precarcinoma Microenvironment – Speaker: T. Orellana

#SGOMtg Role of Mesenchymal Stem Cells in the Ovarian Cancer Precarcinoma Microenvironment – Speaker: T. Orellana#gyncsm pic.twitter.com/pHODjYeAPv

— Dee Sparacio (@womenofteal) March 20, 2022

Defining the Impact of Chromobox 2 on the Immune Tumor Microenvironment of High Grade Serous Ovarian Carcinoma –  L. Brubaker

#SGOMtg Dr Brubaker CBX2 ( epigenetic transcription regulator has high expression in HGSOC , poor survival.
Mouse study - less tumor when CBX2 knocked down .
CBX2 directly regulates micrenvironment
Working on CBX2 inhibitor . #gyncsm pic.twitter.com/vOkLKxauYx

— Dee Sparacio (@womenofteal) March 20, 2022

 Stay tuned for a post on Cervical Cancer.

Dee

Every Day is a Blessing!